A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
Status:
Active, not recruiting
Trial end date:
2022-02-18
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult
participants with moderate to severe atopic dermatitis (AD).